Prenatal screening for pre-eclampsia: Frequently asked questions

Dagmar Wertaschnigg; Maya Reddy; Ben W.J. Mol; Daniel L. Rolnik; Fabricio da Silva Costa

doi:10.1111/ajo.12982

Prenatal screening for pre-eclampsia: Frequently asked questions

Dagmar Wertaschnigg^*
, Maya Reddy
, Ben W.J. Mol
, Daniel L. Rolnik
, Fabricio da Silva Costa

^*Corresponding author for this work

Monash University
Paracelsus Private Medical University
Monash Women's Maternity Services
Universidade de São Paulo

Research output: Contribution to journal › Review article › peer-review

7 Citations (Scopus)

11 Downloads (Pure)

Abstract

The current approach to screening for pre-eclampsia is based on guidelines that rely on medical and obstetric history in early pregnancy to select a high-risk group that might benefit from low-dose aspirin. However, combined screening tests with the addition of biophysical and biochemical measurements have shown significantly better detection rates for preterm pre-eclampsia. Furthermore, the administration of aspirin for the 10% screen-positive group can lead to a significant reduction in severe and preterm forms of pre-eclampsia. This review aims to answer frequently asked questions related to the clinical implementation of screening and the management of screening results.

Original language	English
Pages (from-to)	477-483
Number of pages	7
Journal	Australian and New Zealand Journal of Obstetrics and Gynaecology
Volume	59
Issue number	4
Early online date	22 May 2019
DOIs	https://doi.org/10.1111/ajo.12982
Publication status	Published - Aug 2019

Funding

Conflicts of 阀nteresBt:WJM is sup ported by a NHMRC Practitioner Fellowship (GNT1082548). BWJM reports consultancy for ObsEva, Merck KGaA and Guerbet. MR is supported by a NHMRC Postgraduate Scholarship (GNT1151281) and RANZCOG Fotheringham Scholarship. The other authors report no conflicts of interest. Dagmar Wertaschnigg was supported by a grant from the Paracelsus Medical University Salzburg, Austria (PMU Research Fund – PMU FFF Number: L-18/02/006-WET) and by Drs Haackert Foundation, Germany.

Keywords

aspirin
hypertensive disorders in pregnancy
pre-eclampsia
prevention
screening

Access to Document

10.1111/ajo.12982Licence: CC BY

Weraschnigg_etal_ajo_Prenatal_VOR
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0/
Final published version, 173 KBLicence: CC BY

Cite this

@article{3298ec801fd44806a8c37cf7368a2dfb,

title = "Prenatal screening for pre-eclampsia: Frequently asked questions",

abstract = "The current approach to screening for pre-eclampsia is based on guidelines that rely on medical and obstetric history in early pregnancy to select a high-risk group that might benefit from low-dose aspirin. However, combined screening tests with the addition of biophysical and biochemical measurements have shown significantly better detection rates for preterm pre-eclampsia. Furthermore, the administration of aspirin for the 10\% screen-positive group can lead to a significant reduction in severe and preterm forms of pre-eclampsia. This review aims to answer frequently asked questions related to the clinical implementation of screening and the management of screening results.",

keywords = "aspirin, hypertensive disorders in pregnancy, pre-eclampsia, prevention, screening",

author = "Dagmar Wertaschnigg and Maya Reddy and Mol, \{Ben W.J.\} and Rolnik, \{Daniel L.\} and \{da Silva Costa\}, Fabricio",

year = "2019",

month = aug,

doi = "10.1111/ajo.12982",

language = "English",

volume = "59",

pages = "477--483",

journal = "Australian and New Zealand Journal of Obstetrics and Gynaecology",

issn = "0004-8666",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Prenatal screening for pre-eclampsia

T2 - Frequently asked questions

AU - Wertaschnigg, Dagmar

AU - Reddy, Maya

AU - Mol, Ben W.J.

AU - Rolnik, Daniel L.

AU - da Silva Costa, Fabricio

PY - 2019/8

Y1 - 2019/8

N2 - The current approach to screening for pre-eclampsia is based on guidelines that rely on medical and obstetric history in early pregnancy to select a high-risk group that might benefit from low-dose aspirin. However, combined screening tests with the addition of biophysical and biochemical measurements have shown significantly better detection rates for preterm pre-eclampsia. Furthermore, the administration of aspirin for the 10% screen-positive group can lead to a significant reduction in severe and preterm forms of pre-eclampsia. This review aims to answer frequently asked questions related to the clinical implementation of screening and the management of screening results.

AB - The current approach to screening for pre-eclampsia is based on guidelines that rely on medical and obstetric history in early pregnancy to select a high-risk group that might benefit from low-dose aspirin. However, combined screening tests with the addition of biophysical and biochemical measurements have shown significantly better detection rates for preterm pre-eclampsia. Furthermore, the administration of aspirin for the 10% screen-positive group can lead to a significant reduction in severe and preterm forms of pre-eclampsia. This review aims to answer frequently asked questions related to the clinical implementation of screening and the management of screening results.

KW - aspirin

KW - hypertensive disorders in pregnancy

KW - pre-eclampsia

KW - prevention

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=85066841657&partnerID=8YFLogxK

U2 - 10.1111/ajo.12982

DO - 10.1111/ajo.12982

M3 - Review article

C2 - 31119729

AN - SCOPUS:85066841657

SN - 0004-8666

VL - 59

SP - 477

EP - 483

JO - Australian and New Zealand Journal of Obstetrics and Gynaecology

JF - Australian and New Zealand Journal of Obstetrics and Gynaecology

IS - 4

ER -

Prenatal screening for pre-eclampsia: Frequently asked questions

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this